Document Detail


Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
MedLine Citation:
PMID:  15780207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Alendronate, a nitrogen-containing bisphosphonate is a specific inhibitor of bone resorption and now in the forefront of treatment of osteoporosis. In this study, we reported a significant increase in bone mineral density (BMD) of the spine and the hip in postmenopausal women taking alendronate at 10 mg/d for 1, 2 and 3 years. METHODS: Participants had received daily, oral, 10 mg dose of alendronate for one to three years and placed into one of three groups according to alendronate treatment duration: 41 women received alendronate for 1 year (group I), 46 received alendronate for 2 years (group II), and 30 received alendronate for 3 years (group III). Measurements of bone density had been made by dual energy X-ray absorbtiometry once each year. RESULTS: The differences in L2-L4, L2, L4, femoral neck and trochanter BMD values before and after treatment for first group were significantly different. In second group, significant differences between initial and after treatment were found at the other sites except at the Ward's triangle. In the third group, only a significant increase in the L2-L4, L2, L3, L4, trochanter BMD values between before treatment and at the end of third year was found. Comparisons between groups were performed with Student's t test. ANOVA was used to test the age, menopause age, menopause duration and initial BMD values between the three groups. Calculated P values of less than 0.05 were considered statistically significant. CONCLUSIONS: Alendronate had increased BMD significantly at the spine and hip in postmenopausal women over three years. Increases of BMD in third group were significant during the first and second years. However, continued therapy with alendronate had been required to maintain the gain in BMD over the third year.
Authors:
Ferda Ozdemir; Meliha Rodoplu
Related Documents :
9351877 - Identification of metabolic bone disease in patients with endogenous hyperthyroidism: r...
11489147 - Birthweight, vitamin d receptor genotype and the programming of osteoporosis.
18974917 - Relation between fibroblast growth factor-23, body weight and bone mineral density in e...
16869717 - Dimensions and volumetric bmd of the proximal femur and their relation to age among old...
11787557 - Evaluation of denture stomatitis in croatian adult population.
16215337 - Age and the experience of chronic pain: differences in health and quality of life among...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  118     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-22     Completed Date:  2005-05-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  383-90     Citation Subset:  IM    
Affiliation:
Department of Physical Medicine and Rehabilitation, Trakya University School of Medicine, Edirne, Turkey. ferdadr@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorptiometry, Photon
Adult
Aged
Alendronate / therapeutic use*
Analysis of Variance
Bone Density / drug effects*
Bone Resorption / prevention & control*
Female
Hip / physiopathology
Humans
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*
Spine / physiopathology
Chemical
Reg. No./Substance:
66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction mo...
Next Document:  Effects of extract of Ginkgo biloba with venlafaxine on brain injury in a rat model of depression.